search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Pre-emptive, OCT guided angioplasty of vulnerable, intermediate coronary lesions: a randomized trial, the ‘PECTUS’ Trial


- candidate number23469
- NTR NumberNTR5590
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR8-dec-2015
- Secondary IDsNL55011.029.15 METc VUMC 
- Public TitlePre-emptive, OCT guided angioplasty of vulnerable, intermediate coronary lesions: a randomized trial, the ‘PECTUS’ Trial
- Scientific TitlePre-emptive, OCT guided angioplasty of vulnerable, intermediate coronary lesions: a randomized trial, the ‘PECTUS’ Trial
- ACRONYMPECTUS
- hypothesisStenting with a bioabsorbable vascular scaffold of intermediate, vulnerable coronary lesions in patients with residual non-obstructive CAD after myocardial infarction will prevent future Major Adverse Cardiac Events (MACE)
- Healt Condition(s) or Problem(s) studiedCoronary artery disease, Coronary atherosclerosis
- Inclusion criteria· Informed consent must be obtained
· Patients with STEMI or NSTEMI and residual, non-obstructive CAD, with the possibility of plaque vulnerability.
· The coronary lesion must be suitable for PCI with a commercially available BVS.
- Exclusion criteria· Refusal or inability to provide informed consent.
· < 18 years of age
· Previous CABG.
· Indication for revascularization by CABG.
· Target vessel diameter < 2,5 mm or >4.0 mm
· Anatomy or lesions unsuitable for OCT catheter crossing or imaging (aorta-ostial lesions, small diameter segment, severe calcifications)
· Anatomy unsuitable for BVS placement (left main, bifurcation stenting, sidebranch (> 2 mm) involvement).
· Target lesion is instent restenosis
· Target lesion is chronic total occlusion
· Severe kidney disease defined as an eGFR < 30 ml/min.
· Pregnancy.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 4-mrt-2016
- planned closingdate1-mrt-2023
- Target number of participants500
- InterventionsAfter inclusion, patients will undergo coronary CT and OCT to determine if the residual stenosis is vulnerable. In case of vulnerable plaques at OCT, patients will be randomized to PCI with BVS placement or to conservative (optimal medical) therapy.
- Primary outcomeA composite of major adverse cardiovascular events (all cause mortality, non-fatal myocardial infarction (STEMI or NSTEMI), or unplanned revascularization) at one year follow-up
- Secondary outcomeThe same composite at 2 and 5 years
- Timepoints1, 2 and 5 years
- Trial web site
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESMD. PhD. Niels Royen, van
- CONTACT for SCIENTIFIC QUERIESMD. PhD. Niels Royen, van
- Sponsor/Initiator VU University Medical Center
- Funding
(Source(s) of Monetary or Material Support)
Abbott Vascular, St. Jude Medical
- Publications
- Brief summary
- Main changes (audit trail)
- RECORD8-dec-2015 - 22-mei-2016


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl